Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Leucine Amide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 2/20 | 0.37 |
| ▸ | CACNB3 known ✓ | P54284 | 1/20 | 0.37 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.37 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.37 |
| ▸ | CACNA2D2 known ✓ | Q9NY47 | 1/20 | 0.37 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 7/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 4/20 | 0.44 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 2/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucinamide SCHEMBL1881755 | 1.00 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucinamide SCHEMBL1425296 | 1.00 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucinamide SCHEMBL241527 | 0.97 | — | — | |
| Leucinamide SCHEMBL1989213 | 0.97 | — | — | |
| Leucine Amide SCHEMBL241528 | 0.97 | — | — | |
| Leucine Amide SCHEMBL8081226 | 0.95 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucinamide SCHEMBL8081225 | 0.95 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine Amide SCHEMBL8052964 | 0.95 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine Amide SCHEMBL9274582 | 0.95 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucinamide SCHEMBL8052962 | 0.95 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0397652-B1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORP (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0397652-A4 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | — | 1991-04-03 | — | — | EP | claimed |
| EP-0397652-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID. | GENZYME CORP (US) | 1990-11-22 | — | — | EP | claimed |
| US-4937270-A | Water insoluble derivatives of hyaluronic acid | GENZYME CORPORATION (US) | 1990-06-26 | — | — | US | claimed |
| WO-1989002445-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORPORATION (US) | 1989-03-23 | — | — | WO | claimed |
| US-12559514-B2 | Synthesis of fluorinated nucleotides | MERCK SHARP & DOHME LLC (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260027071-A1 | COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID | KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) | 2026-01-29 | — | — | US | disclosed |
| US-20260014098-A1 | FENCHOL AS A STIMULATOR OF FREE FATTY ACID RECEPTOR AND OTHER USES THEREOF | UNIV SOUTH FLORIDA (US) | 2026-01-15 | — | — | US | disclosed |
| US-12447135-B2 | Fenchol as a stimulator of free fatty acid receptor and other uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4483868-A1 | COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID | Boo, Yong Chool (KR) | 2025-01-01 | — | — | EP | disclosed |
| US-20240218009-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240182511-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-06-06 | — | — | US | disclosed |
| EP-0326799-A2 | Enzymatic process for synthesizing peptides | Degussa Aktiengesellschaft (DE) | 1989-08-09 | — | — | EP | disclosed |
| WO-1989002445-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORPORATION (US) | 1989-03-23 | — | — | WO | disclosed |
| WO-1988006890-A1 | SYNTHETIC INHIBITORS OF MAMMALIAN COLLAGENASE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1988-09-22 | — | — | WO | disclosed |
| US-4452814-A | ANTITUMOR AGENTS | SUAMI T (JP) | 1984-06-05 | — | — | US | disclosed |
| US-4443367-A | SYNTHETIC | MONSANTO COMPANY (US) | 1984-04-17 | — | — | US | disclosed |
| US-4425428-A | Novel peptide and peptolide substrates for mammalian collagenase | MONSANTO COMPANY (US) | 1984-01-10 | — | — | US | disclosed |
| US-4384993-A | FRACTURING IN PRESENCE OF WATER SOLUBLE NITROGEN COMPOUND | JURIDICAL FOUNDATION THE CHEMO SERO-THERAPEUTIC RESEARCH INSTITUTE (JP) | 1983-05-24 | — | — | US | disclosed |
| EP-0035616-A1 | Production of immunoglobulin having a high monomer content | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute (JP) | 1981-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218009-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | STING1, IFNAR1, CGAS | CACNA2D1 4288/4885CACNB3 4458/4885CACNA1C 4394/4885 |
| US-20260027071-A1 | COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID | COL2A1, COL14A1, GLS | CACNA2D1 970/4885CACNB3 3220/4885CACNA1C 3292/4885 |
| US-20260014098-A1 | FENCHOL AS A STIMULATOR OF FREE FATTY ACID RECEPTOR AND OTHER USES THEREOF | FFAR2, FFAR1, FFAR3 | CACNA2D1 2017/4885CACNB3 438/4885CACNA1C 599/4885 |
| US-12447135-B2 | Fenchol as a stimulator of free fatty acid receptor and other uses thereof | FFAR2, FFAR1, FFAR3 | CACNA2D1 3898/4885CACNB3 1011/4885CACNA1C 1439/4885 |
| US-12559514-B2 | Synthesis of fluorinated nucleotides | NUDT1, NSUN2, PNP | CACNA2D1 336/4885CACNB3 2210/4885CACNA1C 855/4885 |
| US-20240182511-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | STING1, IFNAR1, CGAS | CACNA2D1 3656/4885CACNB3 4547/4885CACNA1C 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.